Yunfei F. Chen

Tianjin, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications

External validation of the AAA+ survival model in a large Chinese cohort with essential thrombocythaemia.

External validation of the AAA+ survival model in a large Chinese cohort with essential thrombocythaemia.

Journal: British journal of haematology
Published: April 16, 2026

No significant increase in thrombotic risk following the widespread adoption of TPO-RAs in ITP: A comparative study.

No significant increase in thrombotic risk following the widespread adoption of TPO-RAs in ITP: A comparative study.

Journal: Global medical genetics
Published: March 12, 2026

Clinical heterogeneity in congenital factor XII deficiency: Coexisting risk factors in thrombotic and bleeding events.

Clinical heterogeneity in congenital factor XII deficiency: Coexisting risk factors in thrombotic and bleeding events.

Journal: British journal of haematology
Published: February 24, 2026

Towards achieving immune reset in autoimmune cytopenias: Insights from clinical experiences with B cell depleting therapies.

Towards achieving immune reset in autoimmune cytopenias: Insights from clinical experiences with B cell depleting therapies.

Journal: Blood reviews
Published: December 27, 2025

Long-term efficacy and safety of low-dose rituximab in immune thrombocytopenia: a multicentre, prospective, open-label, randomised controlled trial.

Long-term efficacy and safety of low-dose rituximab in immune thrombocytopenia: a multicentre, prospective, open-label, randomised controlled trial.

Journal: Annals of hematology
Published: November 25, 2025

Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial.

Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial.

Journal: EClinicalMedicine
Published: November 05, 2025

Efficacy and safety of eltrombopag in the treatment of cancer therapy-induced thrombocytopenia: a large-scale, multicenter, retrospective study in China.

Efficacy and safety of eltrombopag in the treatment of cancer therapy-induced thrombocytopenia: a large-scale, multicenter, retrospective study in China.

Journal: Blood science (Baltimore, Md.)
Published: October 24, 2025

Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.

Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.

Journal: BMJ (Clinical research ed.)
Published: October 21, 2025

The effectiveness and safety of various treatments for hemophilia in China: a literature review and evidence mapping.

The effectiveness and safety of various treatments for hemophilia in China: a literature review and evidence mapping.

Journal: Hematology (Amsterdam, Netherlands)
Published: October 06, 2025

Phase 1 pilot study for hemophilia-A: AAV8 vector with prophylactic tacrolimus-glucocorticoid achieves therapeutic FVIII activity.

Phase 1 pilot study for hemophilia-A: AAV8 vector with prophylactic tacrolimus-glucocorticoid achieves therapeutic FVIII activity.

Journal: Signal transduction and targeted therapy
Published: September 26, 2025

Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial.

Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial.

Journal: Nature medicine
Published: July 25, 2025

Bone marrow proteomic profiling reveals TMEM109 as a biomarker for relapse in thrombotic thrombocytopenic purpura.

Bone marrow proteomic profiling reveals TMEM109 as a biomarker for relapse in thrombotic thrombocytopenic purpura.

Journal: Journal of thrombosis and haemostasis : JTH
Published: July 24, 2025
Showing 1-12 of 64

Last Updated: 09/26/2026